Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21520224 | 0.76 | GPR3 (0.38) | GPR3HTR2ACHRM2HTR1AADRA2A | |
| SCHEMBL21797756 | 0.71 | ALDH1A1 (0.33) | — | |
| SCHEMBL6918933 | 0.71 | HTR6 (0.32) | HTR2A | |
| SCHEMBL21110508 | 0.68 | — | — | |
| SCHEMBL29085623 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL8021667 | 0.65 | GPR3 (0.39) | GPR3HTR2ACHRM2HTR1AADRA2A | |
| SCHEMBL23859909 | 0.65 | ELANE (0.37) | GPR3 | |
| SCHEMBL27330185 | 0.64 | GPR3 (0.46) | GPR3HTR2ACHRM2HTR1AADRA2A | |
| SCHEMBL29950614 | 0.64 | GPR3 (0.50) | GPR3HTR2ACHRM2HTR1AADRA2A | |
| SCHEMBL524603 | 0.64 | GPR3 (0.50) | GPR3HTR2ACHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141606-A1 | Alkylation of Transition Metal Coordination Catalyst Complexes | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021194831-A1 | ALKYLATION OF TRANSITION METAL COORDINATION CATALYST COMPLEXES | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141606-A1 | Alkylation of Transition Metal Coordination Catalyst Complexes | AS3MT, AP1M1, AP3M1 | GPR3 3916/4885HTR2A 4311/4885CHRM2 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.